- Asia Markets Fall After Wall Street's Slide
- Yum Posts Higher Profit on Rising Operations in China
- Alcoa Profit Halves; Firm to Curtail Spending
- Fed View On Economy Grew Darker in September
- Text: FOMC Minutes
- The Duplicitous Sheila Bair
- Bernanke: Rate Cut Possible to Cure 'Historic' Slump
- Pros Ands Cons For A Rate Cut
- Fed's Moves Will Solve 'Bear of a Problem': Stern
- Mad Mail: Does the Gov't Favor Citigroup?
- Lightning Round OT: US Airways, Medco and More
- Your First Move For Wednesday October 8th
- Lightning Round: GameStop, Forward Air, Packaging Corp. and More
- Web Extra: Cash-Rich Tech
- Your Questions About... Short-Selling, RBS
- Where Are The Buying Opportunities?
- Executive Decision: Salesforce.com CEO Marc Benioff
- When Will Tech Bottom?
- UAW: health care trust needs automakers' cash
- MetLife says will offer 75M shares of common stock
- MetLife says 3Q trimmed by market downturn
- Brazil's president expects Ecuador-Petrobras deal
- Mexico to revise 2009 budget to ease crisis spread
- Chevron loses NY ruling on rainforest issue
- Earnings roundup: Alcoa, Yum Brands
- Analyst says Wachovia bids could come at a cost
- Movers roundup: Bank of America, IBM
- Movers roundup: G&K Services, GE
Generic version of Risperdal gains FDA OK
Text Size 
Teva won approval for a generic version of the popular anti-psychotic drug
NEW YORK - Johnson & Johnson's blockbuster anti-psychotic drug Risperdal will face generic competition, as Teva Pharmaceutical Industries Ltd. on Monday became the first company to receive approval for a generic version.
Israel-based Teva received Food and Drug Administration approval for a generic version of the blockbuster drug, used to treat schizophrenia and bipolar disorder, among other conditions. New Brunswick, N.J.-based Johnson & Johnson's Janssen unit had expected Risperdal's patent expiration this month, followed by tough generic competition over the key revenue driver.
Copyright 2008 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Tools:
Print
Email
Del.icio.us
Digg It
Data is a real-time snapshot *Data is delayed at least 15 minutes